With the rise of osimertinib as a first-line therapy for patients with EGFR-mutant NSCLC and ensuing reduction in the incidence of EGFR T790M–mediated resistance, the share of acquired resistance mediated by MET amplification has increased in patients with EGFR-driven tumors. This evidence concerns the gene MET and non-small cell lung carcinoma.